Gene Therapy Deal Benchmarks in Neurology

Median Upfront

$331M

Range: $163M - $504M

Total Deal Value

$3.0B

Range: $1.8B - $4.2B

Royalty Rate

12.3% - 19.7%

Tiered up to 23.7%

Dev Milestones

$874M

Range: $536M - $1.2B

Model Your Deal

Market Analysis

Gene Therapy therapies in neurology have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 gene therapy asset in neurology is $331M, with total deal values reaching $3.0B. Development milestones average $874M, while regulatory milestones contribute $953M.

The neurology gene therapy landscape is characterized by moderate competitive intensity with significant unmet need in neurodegenerative indications. Disease-modifying therapies and novel CNS delivery platforms are attracting increasing licensee interest following breakthroughs in amyloid-targeted approaches. The recommended deal structure allocates approximately 11% to upfront payments and 89% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for gene therapy neurology deals range from 12.3% to 19.7% at the base tier, with tiered escalation reaching 16.3%-23.7% on blockbuster sales. Commercial milestones averaging $821M further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a gene therapy neurology licensing deal?

Based on our analysis, Phase 2 gene therapy licensing deals in neurology average $331M in upfront payments, with a range of $163M to $504M depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for gene therapy neurology transactions?

The median total deal value for Phase 2 gene therapy assets in neurology is $3.0B, ranging from $1.8B to $4.2B. This includes development milestones ($874M), regulatory milestones ($953M), and commercial milestones ($821M).

What royalty rates are standard for gene therapy deals in neurology?

Base royalty rates for gene therapy neurology transactions range from 12.3% to 19.7%, with tiered escalations reaching 16.3%-23.7% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in gene therapy neurology deals?

Gene Therapy neurology deals allocate approximately 89% of total deal value to milestones. Development milestones ($874M) make up the largest share, followed by commercial milestones ($821M) and regulatory milestones ($953M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Gene Therapy Deal Benchmarks in Neurology

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Small Molecule in Neurology

Monoclonal Antibody in Neurology

Gene Therapy in Oncology

Gene Therapy in Metabolic & Obesity

Ready to Calculate Your Deal Terms?